The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1?:?5 with β-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved β-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs. 1. Introduction Any drug from a given dosage form to be absorbed must be present in the form of solution at the site of absorption. Low aqueous solubility is one of the major problems encountered during formulation development of new chemical entities especially in the process of generic product development. More than 40% of new chemical entities developed in pharmaceutical industry are practically insoluble in water. Various techniques are used for the enhancement of the solubility of poorly soluble drugs including physical and chemical modifications of drug like particle size reduction, crystal engineering, salt formation, solid dispersion, use of surfactant, hydrotropy, cosolvency, use of surfactants, and complexation [1]. Inclusion complexes are formed by the insertion of the nonpolar molecule or the nonpolar region of one molecule into the cavity of another molecule or host molecules. The most commonly used host molecules are cyclodextrins. Cyclodextrins are nonreducing, crystalline, water soluble, cyclic oligosaccharides consisting of glucose monomers arranged in a donut-shaped
References
[1]
R. Narazaki, T. Harada, N. Takami, Y. Kato, and T. Ohwaki, “A new method for disintegration studies of rapid disintegrating tablet,” Chemical and Pharmaceutical Bulletin, vol. 52, no. 6, pp. 704–707, 2004.
[2]
Y. Fu, S. Yang, S. H. Jeong, S. Kimura, and K. Park, “Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 21, no. 6, pp. 433–476, 2004.
[3]
H. Seager, “Drug-delivery products and the Zydis fast-dissolving dosage form,” Journal of Pharmacy and Pharmacology, vol. 50, no. 4, pp. 375–382, 1998.
S. Yang, Y. Fu, S. H. Jeong, and K. Park, “Application of poly(acrylic acid) superporous hydrogel microparticles as a super-disintegrant in fast-disintegrating tablets,” Journal of Pharmacy and Pharmacology, vol. 56, no. 4, pp. 429–436, 2004.
[6]
G. Abdelbary, P. Prinderre, C. Eouani, J. Joachim, J. P. Reynier, and P. Piccerelle, “The preparation of orally disintegrating tablets using a hydrophilic waxy binder,” International Journal of Pharmaceutics, vol. 278, no. 2, pp. 423–433, 2004.
[7]
P. V. Swamy, S. P. Divate, S. B. Shirsand, and P. Rajendra, “Preparation and evaluation of orodispersible tablets of pheniramine maleate by effervescent method,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 2, pp. 151–154, 2009.
[8]
T. Pralhad and K. Rajendrakumar, “Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis,” Journal of Pharmaceutical and Biomedical Analysis, vol. 34, no. 2, pp. 333–339, 2004.
[9]
S. V. Kulkarni, P. R. Kumar, N. Patel, R. B. Someshwara, B. Ramesh, and K. P. Ashok, “Formulation and evaluation of fast disintigrating Meloxicam tablets and its comparison with marketed product,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 1, pp. 91–93, 2011.
[10]
S. Schiermeier and P. C. Schmidt, “Fast dispersible ibuprofen tablets,” European Journal of Pharmaceutical Sciences, vol. 15, no. 3, pp. 295–305, 2002.
[11]
Y. Okuda, Y. Irisawa, K. Okimoto, T. Osawa, and S. Yamashita, “A new formulation for orally disintegrating tablets using a suspension spray-coating method,” International Journal of Pharmaceutics, vol. 382, no. 1-2, pp. 80–87, 2009.
[12]
H. K. Ibrahim and D. A. El-Setouhy, “Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization,” AAPS PharmSciTech, vol. 11, no. 1, pp. 189–196, 2010.
[13]
T. Sushma, A. Y. Khan, R. K. Khar, F. J. Ahmad, and Z. Khan, “Development and characterization of paracetamol complexes with hydroxypropyl-β-cyclodextrin,” Iranian Journal of Pharmaceutical Research, vol. 6, no. 2, pp. 95–99, 2007.
[14]
N. H. Indurwade, T. H. Rajyaguru, and P. D. Nakhat, “Novel approach-fast dissolving tablets,” Indian Drugs, vol. 39, no. 8, pp. 405–409, 2002.
[15]
Y. Kuno, M. Kojima, S. Ando, and H. Nakagami, “Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols,” Journal of Controlled Release, vol. 105, no. 1-2, pp. 16–22, 2005.
[16]
S. C. Arora, P. K. Sharma, R. Irchhaiya, A. Khatkar, N. Singh, and J. Gagoria, “Development, characterization and solubility study of solid dispersion of cefpodoxime proxetil by solvent evaporation method,” International Journal of ChemTech Research, vol. 2, no. 2, pp. 1156–1162, 2010.
[17]
L. S. Koester, C. R. Xavier, P. Mayorga, and V. L. Bassani, “Influence of β-cyclodextrin complexation on carbamazepine release from hydroxypropyl methylcellulose matrix tablets,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 55, no. 1, pp. 85–91, 2003.